Payment overview · 2025
General Payments
$197.60
10 reported records · 10 companies
Healthcare provider profile · identity verified
Patrick J Harris, D O
Allopathic & Osteopathic Physicians|Family Medicine · SAINT AUGUSTINE, FL · NPI 1063525350
Verified facts
What the public records show
CMS Open Payments records show Patrick J Harris, D O received $197.60 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.47 | 16.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.63 | 11.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.24 | 11.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $21.50 | 10.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.30 | 9.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.14 | 9.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.43 | 8.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.89 | 7.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.64 | 7.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.36 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $197.60 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.47 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| ROTARIX Normalized: rotarix |
Biological | GlaxoSmithKline, LLC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
46 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 878 | 369 |
| Amlodipine Besylate | Amlodipine Besylate | 536 | 214 |
| Atorvastatin Calcium | Atorvastatin Calcium | 477 | 194 |
| Omeprazole | Omeprazole | 360 | 168 |
| Lisinopril | Lisinopril | 349 | 152 |
| Losartan Potassium | Losartan Potassium | 339 | 149 |
| Metformin Hcl Er | Metformin Hcl | 280 | 125 |
| Meloxicam | Meloxicam | 252 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 251 | 118 |
| Gabapentin | Gabapentin | 239 | 124 |
| Hydrochlorothiazide | Hydrochlorothiazide | 227 | 96 |
| Ezetimibe | Ezetimibe | 182 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 86 |
| Pioglitazone Hcl | Pioglitazone Hcl | 173 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 61 |
| Sertraline Hcl | Sertraline Hcl | 129 | 62 |
| Furosemide | Furosemide | 127 | 65 |
| Montelukast Sodium | Montelukast Sodium | 124 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 114 | 59 |
| Azithromycin | Azithromycin | 113 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 49 |
| Simvastatin | Simvastatin | 99 | 41 |
| Fenofibrate | Fenofibrate | 98 | 45 |
| Metformin Hcl | Metformin Hcl | 94 | 44 |
| Trazodone Hcl | Trazodone Hcl | 94 | 53 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 34 |
| Prednisone | Prednisone | 90 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 39 |
| Eliquis | Apixaban | 82 | 32 |
| Alendronate Sodium | Alendronate Sodium | 81 | 37 |
| Allopurinol | Allopurinol | 76 | 35 |
| Potassium Chloride | Potassium Chloride | 76 | 41 |
| Carvedilol | Carvedilol | 71 | 35 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 70 | 34 |
| Celecoxib | Celecoxib | 69 | 34 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 68 | 64 |
| Famotidine | Famotidine | 67 | 35 |
| Atenolol | Atenolol | 66 | 26 |
| Bupropion Xl | Bupropion Hcl | 64 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 22 |
| Amoxicillin | Amoxicillin | 55 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 34 |
| Buspirone Hcl | Buspirone Hcl | 53 | 30 |
| Fluconazole | Fluconazole | 50 | 36 |
| Donepezil Hcl | Donepezil Hcl | 48 | 25 |
| Finasteride | Finasteride | 48 | 26 |
| Spironolactone | Spironolactone | 48 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 22 |
| Tresiba | Insulin Degludec | 46 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 23 |
| Invokana | Canagliflozin | 44 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | 18 |
| Alprazolam | Alprazolam | 38 | 15 |
| Baclofen | Baclofen | 38 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 18 |
| Ketoconazole | Ketoconazole | 38 | 17 |
| Glimepiride | Glimepiride | 37 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 28 |
| Ibuprofen | Ibuprofen | 33 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | 19 |
| Clonidine Hcl | Clonidine Hcl | 31 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | 17 |
| Temazepam | Temazepam | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | 15 |
| Meclizine Hcl | Meclizine Hcl | 30 | 14 |
| Cephalexin | Cephalexin | 28 | 27 |
| Digoxin | Digoxin | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 17 |
| Januvia | Sitagliptin Phosphate | 27 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 27 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 21 |
| Lorazepam | Lorazepam | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 25 |
| Naproxen | Naproxen | 25 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Glipizide | Glipizide | 24 | 13 |
| Nifedipine Er | Nifedipine | 24 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | 14 |
| Verapamil Er | Verapamil Hcl | 23 | 11 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Estradiol | Estradiol | 22 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | 12 |
| Ondansetron Odt | Ondansetron | 22 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Primidone | Primidone | 21 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Ibu | Ibuprofen | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | 11 |
| Mirtazapine | Mirtazapine | 16 | 11 |
| Ozempic | Semaglutide | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $197.60 · 10 records | ABBVIE INC. | BEXSERO, CAPVAXIVE, Cologuard Collection Kit, GARDASIL 9, Leqembi, MOUNJARO, OTEZLA, PEDIARIX, REPATHA, ROTARIX, SPRAVATO, VRAYLAR, Veozah, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error